| (Values in U.S. Thousands) | Dec, 2018 | Dec, 2017 | Dec, 2016 | Dec, 2015 | Dec, 2014 |
| Sales | 2,220 | 19,570 | 18,240 | 15,040 | 4,790 |
| Sales Growth | -88.66% | +7.29% | +21.28% | +213.99% | +166.11% |
| Net Income | -8,420 | -25,710 | -28,240 | -26,020 | -25,450 |
| Net Income Growth | +67.25% | +8.96% | -8.53% | -2.24% | -15.79% |
Adynxx Inc (ADYX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Adynxx Inc. is a clinical-stage biopharmaceutical company. It is focused on therapeutics for the treatment of pain and inflammatory diseases. Adynxx Inc., formerly known as Alliqua BioMedical Inc., is based in San Francisco, United States.
Fiscal Year End Date: 12/31